Japan’s Fujifilm Holdings Corp will buy a drugmaking business from U.S.-based Biogen Inc for about $890 million to try to bolster its healthcare business as growth at its legacy photocopy operations stagnates.
Bristol-Myers Squibb Co’s top shareholder Wellington Management said on Wednesday it does not support the U.S. drugmaker’s $74 billion deal to buy biotech Celgene Corp, imperiling what would be the largest pharmaceutical acquisition of all time.
Initiative to Provide $17.6 Million to 30 U.S. Organizations to Elevate the Work of Community Groups and Provide Support Needed to Strengthen Care for People Aging with HIV
Ipsen (Euronext: IPN; ADR: IPSEY) and Clementia Pharmaceuticals (NASDAQ: CMTA) today announced that they have entered into an agreement for Ipsen to acquire Clementia Pharmaceuticals, including its key late-stage clinical asset palovarotene, an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of fibrodysplasia ossificans progressiva (FOP), multiple osteochondromas (MO) and other diseases. The acquisition will proceed by way of a court-approved plan of arrangement pursuant to the Canada Business Corporations Act.
Focused on creating the next frontier of surgery, Johnson & Johnson (NYSE: JNJ), today announced that Ethicon, Inc., entered into a definitive agreement to acquire Auris Health, Inc. for approximately $3.4 billion in cash.
Taisho Pharmaceutical Holdings Co. is nearing a deal to buy Bristol-Myers Squibb Co.’s French over-the-counter unit, people familiar with the matter said, as the Japanese drugmaker seeks to boost its overseas presence.